The global Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body"s immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).
United States market for Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Vaccine players cover AstraZeneca, BioNTech, Boehringer-Ingelheim, CCBIO, CSL, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淰accine Industry Forecast鈥� looks at past sales and reviews total world Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Vaccine sales for 2025 through 2031. With Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine market by product type, application, key players and key regions and countries.
Segmentation by Type:
Varicella Vaccine
Influenza Vaccine
Polio Vaccine
Hepatitis A Vaccine
Rabies Vaccine
BCG Vaccine
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Others
Segmentation by Application:
For Adult
For Child
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
BioNTech
Boehringer-Ingelheim
CCBIO
CSL
CureVac
Elanco
GSK
Hulan Bio
Indian Immunologicals
Merck
Minhai Biotechnology
Mitsubishi Tanabe Pharma
Moderna Therapeutics
Mylan
Plumbline Life Sciences
Sanofi
Translate Bio
Walvax Biotechnology
Wuhan Institute of Biological Products
Zoties
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Vaccine 麻豆原创 Size (2020-2031)
2.1.2 Vaccine 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Vaccine by Country/Region (2020, 2024 & 2031)
2.2 Vaccine Segment by Type
2.2.1 Varicella Vaccine
2.2.2 Influenza Vaccine
2.2.3 Polio Vaccine
2.2.4 Hepatitis A Vaccine
2.2.5 Rabies Vaccine
2.2.6 BCG Vaccine
2.2.7 Hepatitis B
2.2.8 Pertussis, Diphtheria, Tetanus
2.2.9 Pneumococcal
2.3 Vaccine 麻豆原创 Size by Type
2.3.1 Vaccine 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Vaccine 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Vaccine Segment by Application
2.4.1 For Adult
2.4.2 For Child
2.5 Vaccine 麻豆原创 Size by Application
2.5.1 Vaccine 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Vaccine 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Vaccine 麻豆原创 Size by Player
3.1 Vaccine 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Vaccine Revenue by Player (2020-2025)
3.1.2 Global Vaccine Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Vaccine Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Vaccine by Region
4.1 Vaccine 麻豆原创 Size by Region (2020-2025)
4.2 Global Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Vaccine 麻豆原创 Size Growth (2020-2025)
4.4 APAC Vaccine 麻豆原创 Size Growth (2020-2025)
4.5 Europe Vaccine 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Vaccine 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Vaccine 麻豆原创 Size by Country (2020-2025)
5.2 Americas Vaccine 麻豆原创 Size by Type (2020-2025)
5.3 Americas Vaccine 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccine 麻豆原创 Size by Region (2020-2025)
6.2 APAC Vaccine 麻豆原创 Size by Type (2020-2025)
6.3 APAC Vaccine 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Vaccine 麻豆原创 Size by Country (2020-2025)
7.2 Europe Vaccine 麻豆原创 Size by Type (2020-2025)
7.3 Europe Vaccine 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Vaccine by Region (2020-2025)
8.2 Middle East & Africa Vaccine 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Vaccine 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Vaccine 麻豆原创 Forecast
10.1 Global Vaccine Forecast by Region (2026-2031)
10.1.1 Global Vaccine Forecast by Region (2026-2031)
10.1.2 Americas Vaccine Forecast
10.1.3 APAC Vaccine Forecast
10.1.4 Europe Vaccine Forecast
10.1.5 Middle East & Africa Vaccine Forecast
10.2 Americas Vaccine Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Vaccine Forecast
10.2.2 Canada 麻豆原创 Vaccine Forecast
10.2.3 Mexico 麻豆原创 Vaccine Forecast
10.2.4 Brazil 麻豆原创 Vaccine Forecast
10.3 APAC Vaccine Forecast by Region (2026-2031)
10.3.1 China Vaccine 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Vaccine Forecast
10.3.3 Korea 麻豆原创 Vaccine Forecast
10.3.4 Southeast Asia 麻豆原创 Vaccine Forecast
10.3.5 India 麻豆原创 Vaccine Forecast
10.3.6 Australia 麻豆原创 Vaccine Forecast
10.4 Europe Vaccine Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Vaccine Forecast
10.4.2 France 麻豆原创 Vaccine Forecast
10.4.3 UK 麻豆原创 Vaccine Forecast
10.4.4 Italy 麻豆原创 Vaccine Forecast
10.4.5 Russia 麻豆原创 Vaccine Forecast
10.5 Middle East & Africa Vaccine Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Vaccine Forecast
10.5.2 South Africa 麻豆原创 Vaccine Forecast
10.5.3 Israel 麻豆原创 Vaccine Forecast
10.5.4 Turkey 麻豆原创 Vaccine Forecast
10.6 Global Vaccine Forecast by Type (2026-2031)
10.7 Global Vaccine Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Vaccine Forecast
11 Key Players Analysis
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Vaccine Product Offered
11.1.3 AstraZeneca Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 BioNTech
11.2.1 BioNTech Company Information
11.2.2 BioNTech Vaccine Product Offered
11.2.3 BioNTech Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 BioNTech Main Business Overview
11.2.5 BioNTech Latest Developments
11.3 Boehringer-Ingelheim
11.3.1 Boehringer-Ingelheim Company Information
11.3.2 Boehringer-Ingelheim Vaccine Product Offered
11.3.3 Boehringer-Ingelheim Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Boehringer-Ingelheim Main Business Overview
11.3.5 Boehringer-Ingelheim Latest Developments
11.4 CCBIO
11.4.1 CCBIO Company Information
11.4.2 CCBIO Vaccine Product Offered
11.4.3 CCBIO Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 CCBIO Main Business Overview
11.4.5 CCBIO Latest Developments
11.5 CSL
11.5.1 CSL Company Information
11.5.2 CSL Vaccine Product Offered
11.5.3 CSL Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 CSL Main Business Overview
11.5.5 CSL Latest Developments
11.6 CureVac
11.6.1 CureVac Company Information
11.6.2 CureVac Vaccine Product Offered
11.6.3 CureVac Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 CureVac Main Business Overview
11.6.5 CureVac Latest Developments
11.7 Elanco
11.7.1 Elanco Company Information
11.7.2 Elanco Vaccine Product Offered
11.7.3 Elanco Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Elanco Main Business Overview
11.7.5 Elanco Latest Developments
11.8 GSK
11.8.1 GSK Company Information
11.8.2 GSK Vaccine Product Offered
11.8.3 GSK Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 GSK Main Business Overview
11.8.5 GSK Latest Developments
11.9 Hulan Bio
11.9.1 Hulan Bio Company Information
11.9.2 Hulan Bio Vaccine Product Offered
11.9.3 Hulan Bio Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Hulan Bio Main Business Overview
11.9.5 Hulan Bio Latest Developments
11.10 Indian Immunologicals
11.10.1 Indian Immunologicals Company Information
11.10.2 Indian Immunologicals Vaccine Product Offered
11.10.3 Indian Immunologicals Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Indian Immunologicals Main Business Overview
11.10.5 Indian Immunologicals Latest Developments
11.11 Merck
11.11.1 Merck Company Information
11.11.2 Merck Vaccine Product Offered
11.11.3 Merck Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Merck Main Business Overview
11.11.5 Merck Latest Developments
11.12 Minhai Biotechnology
11.12.1 Minhai Biotechnology Company Information
11.12.2 Minhai Biotechnology Vaccine Product Offered
11.12.3 Minhai Biotechnology Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Minhai Biotechnology Main Business Overview
11.12.5 Minhai Biotechnology Latest Developments
11.13 Mitsubishi Tanabe Pharma
11.13.1 Mitsubishi Tanabe Pharma Company Information
11.13.2 Mitsubishi Tanabe Pharma Vaccine Product Offered
11.13.3 Mitsubishi Tanabe Pharma Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Mitsubishi Tanabe Pharma Main Business Overview
11.13.5 Mitsubishi Tanabe Pharma Latest Developments
11.14 Moderna Therapeutics
11.14.1 Moderna Therapeutics Company Information
11.14.2 Moderna Therapeutics Vaccine Product Offered
11.14.3 Moderna Therapeutics Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Moderna Therapeutics Main Business Overview
11.14.5 Moderna Therapeutics Latest Developments
11.15 Mylan
11.15.1 Mylan Company Information
11.15.2 Mylan Vaccine Product Offered
11.15.3 Mylan Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Mylan Main Business Overview
11.15.5 Mylan Latest Developments
11.16 Plumbline Life Sciences
11.16.1 Plumbline Life Sciences Company Information
11.16.2 Plumbline Life Sciences Vaccine Product Offered
11.16.3 Plumbline Life Sciences Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Plumbline Life Sciences Main Business Overview
11.16.5 Plumbline Life Sciences Latest Developments
11.17 Sanofi
11.17.1 Sanofi Company Information
11.17.2 Sanofi Vaccine Product Offered
11.17.3 Sanofi Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Sanofi Main Business Overview
11.17.5 Sanofi Latest Developments
11.18 Translate Bio
11.18.1 Translate Bio Company Information
11.18.2 Translate Bio Vaccine Product Offered
11.18.3 Translate Bio Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Translate Bio Main Business Overview
11.18.5 Translate Bio Latest Developments
11.19 Walvax Biotechnology
11.19.1 Walvax Biotechnology Company Information
11.19.2 Walvax Biotechnology Vaccine Product Offered
11.19.3 Walvax Biotechnology Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Walvax Biotechnology Main Business Overview
11.19.5 Walvax Biotechnology Latest Developments
11.20 Wuhan Institute of Biological Products
11.20.1 Wuhan Institute of Biological Products Company Information
11.20.2 Wuhan Institute of Biological Products Vaccine Product Offered
11.20.3 Wuhan Institute of Biological Products Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 Wuhan Institute of Biological Products Main Business Overview
11.20.5 Wuhan Institute of Biological Products Latest Developments
11.21 Zoties
11.21.1 Zoties Company Information
11.21.2 Zoties Vaccine Product Offered
11.21.3 Zoties Vaccine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.21.4 Zoties Main Business Overview
11.21.5 Zoties Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
